LIPID-LOWERING THERAPY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
- Authors: Zvenigorodskaya L.A.1, Zvenigorodskaya LA1
-
Affiliations:
- Issue: No 10 (2011)
- Pages: 43-46
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278895
- ID: 278895
Cite item
Full Text
Abstract
One of the major risk factors for cardiovascular disease (CVD) and atherosclerosis is dyslipidemia. The liver plays an important role in the development of disorders of lipid metabolism; so, treatment of CVD involves the application of hepatoprotectors that reasonable from the viewpoint of the pathogenesis of disease. The article presents an algorithm for correction of dyslipidemia and nonalcoholic fatty liver disease.
References
- Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, III пересмотр, 2007 // Приложение к журналу "Кардиоваскулярная терапия и профилактика". М., 2007.
- Карнейро де Мура М. Неалкогольный стеатогепатит // Клинические перспективы в гастроэнтерологии, гепатологии. 2001. № 3. С. 12-5.
Supplementary files
